Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
PureTech Health ( (GB:PRTC) ) has provided an announcement.
PureTech Health announced the results of its Annual General Meeting held on June 16, 2025, where all resolutions were approved, though more than 20% of votes were against the Directors’ Remuneration Report and the re-election of Ms. Mazumdar-Shaw as a Director. The company has engaged with shareholders to address concerns, particularly regarding remuneration practices, and plans to disclose full details in its 2025 Annual Report. The board acknowledges Ms. Mazumdar-Shaw’s value to the company and is committed to resolving scheduling conflicts to ensure better attendance at future meetings.
The most recent analyst rating on (GB:PRTC) stock is a Hold with a £125.00 price target. To see the full list of analyst forecasts on PureTech Health stock, see the GB:PRTC Stock Forecast page.
Spark’s Take on GB:PRTC Stock
According to Spark, TipRanks’ AI Analyst, GB:PRTC is a Neutral.
PureTech Health’s overall score reflects a balance of strong liquidity and promising clinical developments against challenges in profitability and technical weakness. The company’s strategic initiatives and recent positive trial results provide a cautiously optimistic outlook, but operational risks and funding uncertainties remain significant factors.
To see Spark’s full report on GB:PRTC stock, click here.
More about PureTech Health
PureTech Health is a biotherapeutics company that operates using a hub-and-spoke model to transform scientific innovation into value. The company focuses on developing therapeutic candidates with validated pharmacology to address significant patient needs. PureTech Health has successfully brought multiple therapeutic candidates to market, including three that have received U.S. FDA approval.
Average Trading Volume: 730,908
Technical Sentiment Signal: Strong Sell
Current Market Cap: £299.2M
Learn more about PRTC stock on TipRanks’ Stock Analysis page.